Researchers are now using the approach to allow genome-wide sequencing to monitor disease and to investigate treatment response and resistance without the need for tissue biopsy.
Business Insider reports that researchers are making headway in linking genetic variants to mental illness risk.
Alterations affecting the antigen presentation-related gene B2M appeared to be over-represented in melanomas with checkpoint blockade non-response or resistance.
The initiative's four research projects will use use genetic and other technologies to detect and treat cancer at its earliest stages.
A new set of papers reveals a range of gene expression influencers, identified using thousands of samples collected for the Genotype-Tissue Expression project.
Verge is working with four academic institutions to create a broad resource for the translation of preclinical models of amyotrophic lateral sclerosis research.
The newly announced Microbiome Immunity Project seeks to discover links between autoimmune diseases and bacteria in and on the human body.
The collaborators have signed a two-year research and license option agreement to develop novel T-cell therapies for cancer using genome editing technology.
The partners aim to develop a diagnostic methodology for obtaining cancer cell molecular profiles to help guide immunotherapies.
A new BioRxiv preprint says the variants another research team attributed to off-target effects of CRISPR/Cas9 could be natural variation, New Scientist reports.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.